The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a more substantial reduction in body size and benefit metabolic function… Read More